SynCore Biotechnology Co.,Ltd (TPEX:4192)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
24.00
-0.40 (-1.64%)
Jan 22, 2026, 1:10 PM CST

SynCore Biotechnology Co.,Ltd Company Description

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan.

The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer.

It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials.

In addition, the company provides SB05-EndoTAG-1, a conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials.

Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases.

The company has partnerships with Medigene AG, MacuCLEAR Inc.; and Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes NHRI.

SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.

SynCore Biotechnology Co.,Ltd
SynCore Biotechnology Co.,Ltd logo
CountryTaiwan
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees40
CEOMuh-Hwan Su

Contact Details

Address:
84 Chung Shan Road
Yilan City, 269
Taiwan
Phone886 3 958 6101
Websitesyncorebio.com

Stock Details

Ticker Symbol4192
ExchangeTaipei Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyTWD
ISIN NumberTW0004192000
SIC Code2834

Key Executives

NamePosition
Chih-Wen LeeFounder and Chairman of the Board
Dr. Muh-Hwan SuPresident and GM
Wen-Hsin HuangVice President and Head of Drug Development Department
Chia-Hao LiangHead of Financial and General Affairs Department and Accounting Manager
Ruey-Wen LinHead of Quality Assurance Department